All Stories

  1. Could GUCY2C-targeted pharmacotherapy be effective in treating colorectal cancer?

    Article • Expert Review of Clinical Pharmacology, February 2026, Taylor & Francis

    Adam Snook

  2. DSG2-Directed CAR-T Cells Safely and Universally Eliminate Solid Tumors

    Article • February 2026, Springer Science + Business Media

    Adam Snook

  3. A CAR-T Cell-Based Strategy for Eliminating Pathogenic Microglia in ALS

    Article • December 2025, openRxiv

    Adam Snook

  4. Immunotherapy for precision medicine in colorectal cancer

    Article • Expert Review of Precision Medicine and Drug Development, September 2025, Taylor & Francis

    Adam Snook

  5. Cancer Vaccination and Immune-Based Approaches in Pancreatic Cancer

    Article • Cancers, July 2025, MDPI AG

    Adam Snook

  6. CD8α Structural Domains Enhance GUCY2C CAR-T Cell Efficacy

    Article • Cancer Biology & Therapy, September 2024, Taylor & Francis

    Adam Snook

  7. GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults

    Article • npj Parkinson s Disease, April 2024, Springer Science + Business Media

    Adam Snook

  8. Biomarkers for Managing Neurodegenerative Diseases

    Article • Biomolecules, March 2024, MDPI AG

    Adam Snook

  9. Biomarkers for Managing Neurodegenerative Diseases

    Article • March 2024, MDPI AG

    Adam Snook

  10. GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults

    Article • October 2023, Springer Science + Business Media

    Adam Snook

  11. Intestinal neuropod cell GUCY2C regulates visceral pain

    Article • Journal of Clinical Investigation, February 2023, American Society for Clinical Investigation

    Adam Snook

  12. The Poorly Immunogenic Tumor Microenvironment of Pancreatic Cancer: The Impact of Radiation Therapy, and Strategies Targeting Resistance

    Article • Immunotherapy, December 2022, Taylor & Francis

    Adam Snook

  13. Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients

    Article • Expert Review of Clinical Pharmacology, October 2022, Taylor & Francis

    Adam Snook

  14. Guanylyl Cyclase C as a Diagnostic and Therapeutic Target in Colorectal Cancer

    Article • Personalized Medicine, August 2022, Taylor & Francis

    Adam Snook

  15. Immune Checkpoint Inhibitors in Luminal Gastrointestinal Malignancies: Going Beyond MSI-H/dMMR, TMB and PD-L1

    Article • Immunotherapy, June 2022, Taylor & Francis

    Adam Snook

  16. Functional Assessment of Missense Variants in the ABCC6 Gene Implicated in Pseudoxanthoma Elasticum, a Heritable Ectopic Mineralization Disorder

    Article • Journal of Investigative Dermatology, April 2022, Elsevier

    Adam Snook

  17. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma

    Article • Nature Communications, March 2022, Springer Science + Business Media

    Adam Snook

  18. T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C

    Article • Frontiers in Immunology, March 2022, Frontiers

    Adam Snook

  19. Emerging drug targets for colon cancer: A preclinical assessment

    Article • Expert Opinion on Therapeutic Targets, February 2022, Taylor & Francis

    Adam Snook

  20. Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy

    Article • Cancer Biology & Therapy, February 2022, Taylor & Francis

    Adam Snook

  21. Evaluation of CAR-T cell cytotoxicity: Real-time impedance-based analysis

    Article • January 2022, Elsevier

    Adam Snook

  22. Genetic heterogeneity of heritable ectopic mineralization disorders in a large international cohort

    Article • Genetics in Medicine, January 2022, Elsevier

    Adam Snook, Dr Jonathan G Schoenecker

  23. A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer

    Article • Cellular and Molecular Gastroenterology and Hepatology, January 2022, Elsevier

    Adam Snook

  24. Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment

    Article • Vaccines, November 2021, MDPI AG

    Adam Snook

  25. The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission

    Article • Expert Opinion on Biological Therapy, May 2021, Taylor & Francis

    Adam Snook

  26. Emerging Targets for the Diagnosis of Parkinson’S Disease: Examination of Systemic Biomarkers

    Article • Biomarkers in Medicine, May 2021, Taylor & Francis

    Adam Snook

  27. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential

    Article • Expert Opinion on Therapeutic Targets, May 2021, Taylor & Francis

    Adam Snook

  28. Vaccines and Immune Checkpoint Inhibitors: a Promising Combination Strategy in Gastrointestinal Cancers

    Article • Immunotherapy, March 2021, Taylor & Francis

    Adam Snook

  29. Stem Cells as Therapeutic Targets in Colorectal Cancer

    Article • Personalized Medicine, February 2021, Taylor & Francis

    Adam Snook

  30. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer

    Article • Expert Review of Precision Medicine and Drug Development, February 2021, Taylor & Francis

    Adam Snook

  31. From leptin to lasers: the past and present of mouse models of obesity

    Article • Expert Opinion on Drug Discovery, January 2021, Taylor & Francis

    Adam Snook

  32. Guanylyl Cyclase C As A Biomarker for Immunotherapies for the Treatment of Gastrointestinal Malignancies

    Article • Biomarkers in Medicine, January 2021, Taylor & Francis

    Adam Snook

  33. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity

    Article • Journal for ImmunoTherapy of Cancer, August 2020, BMJ

    Adam Snook

  34. Companion vaccines for CAR T-cell therapy: applying basic immunology to enhance therapeutic efficacy

    Article • Future Medicinal Chemistry, June 2020, Future Science

    Adam Snook

  35. Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity

    Article • Cancer Biology & Therapy, June 2020, Taylor & Francis

    Adam Snook

  36. Mobilizing Toxins for Cancer Treatment: Historical Perspectives and Current Strategies

    Article • Toxins, June 2020, MDPI AG

    Adam Snook

  37. Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy

    Article • Toxins, April 2020, MDPI AG

    Adam Snook

  38. pH-Dependent Grafting of Cancer Cells with Antigenic Epitopes Promotes Selective Antibody-Mediated Cytotoxicity

    Article • Journal of Medicinal Chemistry, March 2020, American Chemical Society (ACS)

    Adam Snook

  39. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis

    Article • Cancer Biology & Therapy, February 2020, Taylor & Francis

    Adam Snook

  40. NHERF3 is necessary for Escherichia coli heat-stable enterotoxin-induced inhibition of NHE3: differences in signaling in mouse small intestine and Caco-2 cells

    Article • AJP Cell Physiology, October 2019, American Physiological Society

    Adam Snook

  41. pH-Dependent Grafting of Cancer Cells with Antigenic Epitopes Promotes Selective Antibody-Mediated Cytotoxicity

    Article • September 2019, Cold Spring Harbor Laboratory Press

    Adam Snook

  42. Two distinct GUCY2C circuits with PMV (hypothalamic) and SN/VTA (midbrain) origin

    Article • Brain Structure and Function, September 2019, Springer Science + Business Media

    Adam Snook

  43. Non-thermal plasma-induced immunogenic cell death in cancer

    Article • Journal of Physics D Applied Physics, August 2019, Institute of Physics Publishing

    Adam Snook

  44. Biomarker Targeting of Colorectal Cancer Stem Cells

    Article • Biomarkers in Medicine, August 2019, Taylor & Francis

    Adam Snook

  45. Adenovirus-Mediated ABCC6 Gene Therapy for Heritable Ectopic Mineralization Disorders

    Article • Journal of Investigative Dermatology, June 2019, Elsevier

    Adam Snook

  46. Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia

    Article • Human Pathology, May 2019, Elsevier

    Adam Snook

  47. Therapeutic targeting of gastrointestinal cancer stem cells

    Article • Regenerative Medicine, May 2019, Future Medicine

    Adam Snook

  48. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients

    Article • Journal for ImmunoTherapy of Cancer, April 2019, Springer Science + Business Media

    Adam Snook

  49. TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C

    Article • The Journal of Immunology, January 2019, The American Association of Immunologists

    Adam Snook

  50. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors

    Article • Clinical Pharmacology & Therapeutics, December 2018, Wiley

    Adam Snook

  51. Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress

    Article • Vaccines, July 2018, MDPI AG

    Adam Snook

  52. Non-thermal plasma induces immunogenic cell death in vivo in murine CT26 colorectal tumors

    Article • OncoImmunology, June 2018, Taylor & Francis

    Adam Snook, Vandana Miller

  53. Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases

    Article • Cancer Immunology Research, April 2018, American Association for Cancer Research (AACR)

    Adam Snook

  54. Immunotherapy regimens for metastatic colorectal carcinomas

    Article • Human Vaccines & Immunotherapeutics, October 2017, Taylor & Francis

    Adam Snook

  55. GUCY2C maintains intestinal LGR5+ stem cells by opposing ER stress

    Article • Oncotarget, October 2017, Impact Journals, LLC

    Adam Snook

  56. The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report

    Article • Toxins, September 2017, MDPI AG

    Adam Snook

  57. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome

    Article • Cancer Research, September 2017, American Association for Cancer Research (AACR)

    Adam Snook

  58. ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice

    Article • Toxins, September 2017, MDPI AG

    Adam Snook

  59. Immunotherapy in Colorectal Cancer: Where Are We Now?

    Article • Current Colorectal Cancer Reports, August 2017, Springer Science + Business Media

    Adam Snook

  60. The swinging pendulum of cancer immunotherapy personalization

    Article • Personalized Medicine, May 2017, Future Medicine

    Adam Snook

  61. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer

    Article • Expert Review of Clinical Pharmacology, April 2017, Taylor & Francis

    Adam Snook

  62. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8 + T Cells

    Article • The Journal of Immunology, March 2017, The American Association of Immunologists

    Adam Snook

  63. siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K- ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer

    Article • Molecular Therapy — Nucleic Acids, March 2017, Elsevier

    Adam Snook

  64. RB Loss Promotes Prostate Cancer Metastasis

    Article • Cancer Research, December 2016, American Association for Cancer Research (AACR)

    Adam Dicker, Adam Snook

  65. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope

    Article • Human Gene Therapy Methods, December 2016, Mary Ann Liebert Inc

    Adam Snook

  66. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity

    Article • OncoImmunology, September 2016, Taylor & Francis

    Adam Snook

  67. Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins

    Article • Infection and Immunity, August 2016, ASM Journals

    Adam Snook

  68. A novel role for Cish in the inhibition of TCR signaling

    Article • Translational Cancer Research, June 2016, AME Publishing Company

    Adam Snook

  69. Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer

    Article • Molecular Pharmacology, June 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Adam Snook

  70. Calorie-induced ER stress suppresses uroguanylin satiety signaling in diet-induced obesity

    Article • Nutrition and Diabetes, May 2016, Nature

    Adam Snook

  71. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis

    Article • Cancer Research, January 2016, American Association for Cancer Research (AACR)

    Adam Snook

  72. Targeting guanylate cyclase C in colorectal cancer: Where are we now?

    Article • Drugs of the Future, January 2016, Prous Science

    Adam Snook

  73. Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model

    Article • Molecular Therapy — Nucleic Acids, January 2016, Elsevier

    Adam Snook

  74. Comparative Evaluation of Veriflow® Listeria monocytogenes to USDA and AOAC Culture Based Methods for the Detection of Listeria monocytogenes in Food

    Article • Journal of AOAC International, September 2015, The Journal of AOAC International

    Adam Snook

  75. DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis

    Article • Cancer Cell, July 2015, Elsevier

    Adam Snook

  76. CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia

    Article • Molecular Pharmaceutics, June 2015, American Chemical Society (ACS)

    Adam Snook

  77. Is Financial Literacy Necessary for Radiation Oncology Residents?

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2014, Elsevier

    Adam Snook

  78. Correction: A Novel CDX2 Isoform Regulates Alternative Splicing

    Article • PLOS One, October 2014, PLOS

    Adam Snook

  79. The Paracrine Hormone for the GUCY2C Tumor Suppressor, Guanylin, Is Universally Lost in Colorectal Cancer

    Article • Cancer Epidemiology Biomarkers & Prevention, October 2014, American Association for Cancer Research (AACR)

    Adam Snook

  80. Could targeting T-helper cells aid the development of effective cancer vaccines?

    Article • Immunotherapy, September 2014, Future Medicine

    Adam Snook

  81. A Novel CDX2 Isoform Regulates Alternative Splicing

    Article • PLOS One, August 2014, PLOS

    Adam Snook

  82. Epithelial Immunization Induces Polyfunctional CD8+ T Cells and Optimal Mousepox Protection

    Article • Journal of Virology, June 2014, ASM Journals

    Dr Adam R Hersperger, Adam Snook

  83. Selective antigen-specific CD4+T-cell, but not CD8+T- or B-cell, tolerance corrupts cancer immunotherapy

    Article • European Journal of Immunology, May 2014, Wiley

    Adam Snook

  84. Veriflow® Campylobacter

    Article • Journal of AOAC International, May 2014, The Journal of AOAC International

    Adam Snook

  85. Tumor Radiation Therapy Creates Therapeutic Vaccine Responses to the Colorectal Cancer Antigen GUCY2C

    Article • International Journal of Radiation Oncology*Biology*Physics, April 2014, Elsevier

    Adam Snook

  86. Polyamine-Blocking Therapy Reverses Immunosuppression in the Tumor Microenvironment

    Article • Cancer Immunology Research, October 2013, American Association for Cancer Research (AACR)

    Adam Snook

  87. Intestinal GUCY2C Prevents TGF-  Secretion Coordinating Desmoplasia and Hyperproliferation in Colorectal Cancer

    Article • Cancer Research, October 2013, American Association for Cancer Research (AACR)

    Adam Snook

  88. Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis

    Article • Expert Review of Clinical Pharmacology, September 2013, Informa Healthcare

    Adam Snook

  89. Immunotherapeutic strategies to target prognostic and predictive markers of cancer

    Article • Biomarkers in Medicine, February 2013, Future Medicine

    Adam Snook

  90. GUCY2C Opposes Systemic Genotoxic Tumorigenesis by Regulating AKT-Dependent Intestinal Barrier Integrity

    Article • PLOS One, February 2012, PLOS

    Adam Snook

  91. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C

    Article • Medical Oncology, November 2011, Springer Science + Business Media

    Adam Snook

  92. GUCY2C-targeted cancer immunotherapy: past, present and future

    Article • Immunologic Research, October 2011, Springer Science + Business Media

    Adam Snook

  93. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice

    Article • Journal of Clinical Investigation, September 2011, American Society for Clinical Investigation

    Adam Snook

  94. Functional Macroautophagy Induction by Influenza A Virus without a Contribution to Major Histocompatibility Complex Class II-Restricted Presentation

    Article • Journal of Virology, April 2011, ASM Journals

    Adam Snook

  95. Bacterial Heat-Stable Enterotoxins: Translation of Pathogenic Peptides into Novel Targeted Diagnostics and Therapeutics

    Article • Toxins, August 2010, MDPI AG

    Adam Snook

  96. The Hormone Receptor GUCY2C Suppresses Intestinal Tumor Formation by Inhibiting AKT Signaling

    Article • Gastroenterology, January 2010, Elsevier

    Adam Snook

  97. Bile Acids Initiate Lineage-Addicted Gastroesophageal Tumorigenesis by Suppressing the EGF Receptor-AKT Axis

    Article • Clinical and Translational Science, August 2009, Wiley

    Adam Snook

  98. Lineage-Specific T-Cell Responses to Cancer Mucosa Antigen Oppose Systemic Metastases without Mucosal Inflammatory Disease

    Article • Cancer Research, April 2009, American Association for Cancer Research (AACR)

    Adam Snook

  99. Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer

    Article • Biomarkers in Medicine, February 2009, Future Medicine

    Adam Snook

  100. Cytokine Adjuvanation of Therapeutic Anti-tumor Immunity Targeted to Cancer Mucosa Antigens

    Article • Clinical and Translational Science, December 2008, Wiley

    Adam Snook

  101. Colorectal Cancer Is a Paracrine Deficiency Syndrome Amenable to Oral Hormone Replacement Therapy

    Article • Clinical and Translational Science, September 2008, Wiley

    Adam Snook

  102. Guanylyl Cyclase C-Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity

    Article • JNCI Journal of the National Cancer Institute, June 2008, Oxford University Press (OUP)

    Adam Snook

  103. Derivation and Fluidity of Acutely Induced Dysfunctional CD8+ T Cells

    Article • The Journal of Immunology, April 2008, The American Association of Immunologists

    Adam Snook

  104. Cancer Mucosa Antigens as a Novel Immunotherapeutic Class of Tumor-associated Antigen

    Article • Clinical Pharmacology & Therapeutics, September 2007, Nature

    Adam Snook

  105. The Paracrine Hormone Hypothesis of Colorectal Cancer

    Article • Clinical Pharmacology & Therapeutics, August 2007, Nature

    Adam Snook